scholarly journals Society for Maternal-Fetal Medicine (SMFM) Consult #58: Use of Antenatal Corticosteroids for Individuals at Risk for Late Preterm Delivery

Author(s):  
Uma M. Reddy ◽  
Uma Deshmukh ◽  
Annie Dude ◽  
Lorie Harper ◽  
Sarah Osmundson
2019 ◽  
Vol 173 (5) ◽  
pp. 462 ◽  
Author(s):  
Cynthia Gyamfi-Bannerman ◽  
John A. F. Zupancic ◽  
Grecio Sandoval ◽  
William A. Grobman ◽  
Sean C. Blackwell ◽  
...  

2016 ◽  
Vol 71 (8) ◽  
pp. 453-455 ◽  
Author(s):  
Cynthia Gyamfi-Bannerman ◽  
Elizabeth A. Thom ◽  
Sean C. Blackwell ◽  
Alan T. N. Tita ◽  
Uma M. Reddy ◽  
...  

2018 ◽  
Vol 35 (13) ◽  
pp. 1241-1250 ◽  
Author(s):  
Gloria Too ◽  
George Saade ◽  
Cynthia Gyamfi-Bannerman ◽  
C. Dixon

AbstractSince 1972, the beneficial neonatal effects of antenatal corticosteroids (ACSs) have been repeatedly demonstrated in pregnancies at risk of preterm birth before 34 weeks' gestation. While ACS utilization before 34 weeks has been high since the 1990s, knowledge gaps regarding the risks and benefits of ACS continue to exist. Recent evidence has been published regarding the benefit of ACS in the late preterm period. This review addresses the evidence and knowledge gaps for ACS use before and after 34 weeks' gestation. We also provide recommendations for ACS use in the late preterm period.


Author(s):  
Cynthia Gyamfi-Bannerman ◽  
Kathleen A. Jablonski ◽  
Sean C. Blackwell ◽  
Alan T. N. Tita ◽  
Uma M. Reddy ◽  
...  

Objective In the antenatal late preterm steroids (ALPS) trial betamethasone significantly decreased short-term neonatal respiratory morbidity but increased the risk of neonatal hypoglycemia, diagnosed only categorically (<40 mg/dL). We sought to better characterize the nature, duration, and treatment for hypoglycemia. Study Design Secondary analysis of infants from ALPS, a multicenter trial randomizing women at risk for late preterm delivery to betamethasone or placebo. This study was a reabstraction of all available charts from the parent trial, all of which were requested. Unreviewed charts included those lost to follow-up or from sites not participating in the reabstraction. Duration of hypoglycemia (<40 mg/dL), lowest value and treatment, if any, were assessed by group. Measures of association and regression models were used where appropriate. Results Of 2,831 randomized, 2,609 (92.2%) were included. There were 387 (29.3%) and 223 (17.3%) with hypoglycemia in the betamethasone and placebo groups, respectively (relative risk [RR]: 1.69, 95% confidence interval [CI]: 1.46–1.96). Hypoglycemia generally occurred in the first 24 hours in both groups: 374/385 (97.1%) in the betamethasone group and 214/222 (96.4%) in the placebo group (p = 0.63). Of 387 neonates with hypoglycemia in the betamethasone group, 132 (34.1%) received treatment, while 73/223 (32.7%) received treatment in placebo group (p = 0.73). The lowest recorded blood sugar was similar between groups. Most hypoglycemia resolved by 24 hours in both (93.0 vs. 89.3% in the betamethasone and placebo groups, respectively, p = 0.18). Among infants with hypoglycemia in the first 24 hours, the time to resolution was shorter in the betamethasone group (2.80 [interquartile range: 2.03–7.03) vs. 3.74 (interquartile range: 2.15–15.08) hours; p = 0.002]. Persistence for >72 hours was rare and similar in both groups, nine (2.4%, betamethasone) and four (1.9%, placebo, p = 0.18). Conclusion In this cohort, hypoglycemia was transient and most received no treatment, with a quicker resolution in the betamethasone group. Prolonged hypoglycemia was uncommon irrespective of steroid exposure. Key Points


2016 ◽  
Vol 374 (14) ◽  
pp. 1311-1320 ◽  
Author(s):  
Cynthia Gyamfi-Bannerman ◽  
Elizabeth A. Thom ◽  
Sean C. Blackwell ◽  
Alan T.N. Tita ◽  
Uma M. Reddy ◽  
...  

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Jamie A. Bastek ◽  
Holly Langmuir ◽  
Laxmi A. Kondapalli ◽  
Emmanuelle Paré ◽  
Joanna E. Adamczak ◽  
...  

Objectives. Antenatal corticosteroids (ACS) are not routinely administered to patients at risk for delivery between 34 and 36 6/7 weeks. Our objective was to determine whether ACS are cost-effective for late-preterm infants at risk for imminent preterm delivery. We hypothesized that the preferred strategy <36 weeks would include ACS while the preferred strategy ≥36 weeks would not. Methods. We performed decision-analytic and cost-effectiveness analyses to determine whether ACS was cost-effective at 34, 35, and 36 weeks. We conducted a literature review to determine probability, utility, and cost estimates absent of patient-level data. Base-case cost-effectiveness analysis, univariable sensitivity analysis, and Monte Carlo simulation were performed. A threshold of $100,000/QALY was considered cost-effective. Results. The incremental cost-effectiveness ratio favored the administration of a full course of ACS at 34, 35, and 36 weeks ($62,888.25/QALY, $64,425.67/QALY, and $64,793.71/QALY, resp.). A partial course of ACS was not cost-effective. While ACS was the consistently dominant strategy for acute respiratory outcomes, all models were sensitive to changes in variables associated with chronic respiratory disease. Conclusions. Our findings suggest that the administration of ACS to patients at risk of imminent delivery 34-36 weeks could significantly reduce the cost and acute morbidity associated with late-preterm birth.


Sign in / Sign up

Export Citation Format

Share Document